Demyelinating Diseases: Clinical Trials

4,074 trials for Demyelinating Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2202 completed, 548 unknown, 467 recruiting, 281 terminated. 1399 Not applicable, 597 Phase 2, 393 Phase 3, 359 Phase 1, 233 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable1399Completed 758, Unknown 250, Recruiting 168, Not yet recruiting 76, Active not recruiting 59, Terminated 45, Enrolling by invitation 20, Withdrawn 20, Suspended 3
Phase 2597Completed 318, Terminated 84, Recruiting 57, Unknown 49, Withdrawn 37, Active not recruiting 23, Not yet recruiting 22, Enrolling by invitation 5, Suspended 2
Phase 3393Completed 230, Terminated 50, Active not recruiting 32, Recruiting 32, Unknown 24, Withdrawn 14, Not yet recruiting 9, Enrolling by invitation 1, Suspended 1
Phase 1359Completed 193, Recruiting 42, Terminated 39, Unknown 30, Withdrawn 18, Not yet recruiting 17, Active not recruiting 14, Enrolling by invitation 3, Suspended 3
Phase 4233Completed 135, Terminated 36, Unknown 22, Withdrawn 13, Active not recruiting 12, Recruiting 10, Not yet recruiting 3, Enrolling by invitation 2
Early Phase 143Completed 15, Recruiting 8, Not yet recruiting 6, Unknown 5, Withdrawn 5, Suspended 2, Active not recruiting 1, Terminated 1

Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of Vigorous Versus Low Intensity Cool Room Treadmill Training in People with Multiple Sclerosis
Body-weight supported treadmill training in a room cooled to 16°C - Multiple Sclerosis, Neurological Rehabilitation
Not applicableWithdrawnMemorial University of Newfoundland2030-01-012024-11-27
Blood Biomarkers for Prognostic Stratification in Guillain-Barré Syndrome
Blood Biomarker Panel Assessment (EGR1, EGR2, GBP1, miR-29c, and Piccolo) - Guillain Barré Syndrome
RecruitingAnahuac University1402027-12-012026-11-13
Inductive Therapeutic Exercise in Multiple Sclerosis
Experimental: Inductive Therapeutic Exercise (ETI), Control: Sham Inductive Therapeutic Exercise (sham-ETI) - Multiple Sclerosis
Not applicableNot yet recruitingFundación San Juan De Dios302027-10-012026-10-02
Exploring Reproductive Decision-Making Among Women With Multiple Sclerosis
Multiple Sclerosis
Not yet recruitingAssiut University2722027-06-012026-09-21
IT and IV Lentiviral Gene Therapy for X-ALD
Intrathecal and intravenous LV gene therapy - X-linked Adrenoleukodystrophy
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute302027-06-012026-11-02
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD
Lentiviral TYF-ARSA correction of patient's autologous HSCs - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-06-012026-11-02
Direct Lentiviral Injection Gene Therapy for MLD
Intrathecal and intravenous LV gene therapy - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-05-312026-11-02
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
Phase 2Not yet recruitingMoein Amin202027-03-012026-08-19
A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis
Orca-Q, myeloablative regimen, Tacrolimus - Primary Progressive Multiple Sclerosis, Multiple Sclerosis
Phase 1Not yet recruitingOrca Biosystems, Inc.102027-03-012026-11-13
A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple Sclerosis
Frexalimab, Frexalimab Placebo, Teriflunomide - Multiple Sclerosis
Phase 3Not yet recruitingSanofi25002027-02-152026-11-12
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Phase 1 / Phase 2Not yet recruitingAbelZeta Inc.1192027-02-012026-10-13
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)
Fenebrutinib - Multiple Sclerosis
Phase 3Not yet recruitingHoffmann-La Roche18002027-01-182026-11-16
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
UPLIZNA - Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
RecruitingAmgen602027-01-152026-10-29
Efficacy of Seated Physical Activity INtervention(SPIN) for Wheelchair Users With Multiple Sclerosis
SPIN exercise-training, Control Condition (WELL) - Multiple Sclerosis
Not applicableNot yet recruitingThe University of Texas Health Science Center, Houston1002027-01-042026-10-23
Exercise With and Without Cognitive Training
Effect of Exercise with and Without Cognitive Training on Gait - Multiple Sclerosis
Not applicableNot yet recruitingVA Office of Research and Development302027-01-042026-03-03
Cell-Based Therapy for White Matter Repair in Periventricular Leukomalacia
Investigational Combination Product - Periventricular Leukomalacia, White Matter Disease
Early Phase 1WithdrawnMGAM LLC2027-01-012025-07-22
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV)
Phase 1 / Phase 2Not yet recruitingUniversity Hospital Tuebingen362027-01-012026-11-12
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle
Phase 2WithdrawnMichael, Levy M.D.,Ph.D.2026-12-312025-07-16
Lead Exposure and Multiple Sclerosis
Multiple Sclerosis
Not yet recruitingAssiut University1402026-12-302026-02-20
Local Vibration and Ankle Mobilization in Multiple Sclerosis
Local Vibration, Ankle Joint Mobilization - Multiple Sclerosis
Not applicableNot yet recruitingGaziantep Islam Science and Technology University602026-12-152026-10-19

Showing 20 of 4074. Sign in to see all of them.

Narrower conditions

Multiple Sclerosis (3168)  ·  Multiple Sclerosis, Relapsing-Remitting (617)  ·  Multiple Sclerosis, Chronic Progressive (244)  ·  Fatigue (213)  ·  Motor Activity (174)  ·  Neuromyelitis Optica (172)  ·  Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (136)  ·  Stroke (110)  ·  Parkinson Disease (99)  ·  Guillain-Barre Syndrome (98)  ·  Autoimmune Diseases (78)  ·  Muscle Spasticity (78)  ·  Cognitive Dysfunction (75)  ·  Spinal Cord Injuries (74)

Broader conditions

Nervous System Diseases (4007)  ·  Immune System Diseases (3908)  ·  Autoimmune Diseases of the Nervous System (3863)  ·  Autoimmune Diseases (3839)  ·  Demyelinating Autoimmune Diseases, CNS (3684)  ·  Pathological Conditions, Signs and Symptoms (1191)  ·  Pathologic Processes (689)  ·  Disease Attributes (601)  ·  Signs and Symptoms (574)  ·  Chronic Disease (511)  ·  Central Nervous System Diseases (488)  ·  Brain Diseases (414)  ·  Multiple Sclerosis (401)  ·  Neurologic Manifestations (352)

Interventions

Interferon beta-1a (107)  ·  ocrelizumab (82)  ·  Exercise (72)  ·  Dimethyl Fumarate (70)  ·  Natalizumab (67)  ·  Interferon beta-1b (64)  ·  Fingolimod Hydrochloride (58)  ·  Glatiramer Acetate (55)  ·  Rituximab (43)  ·  teriflunomide (41)  ·  Blood Specimen Collection (40)  ·  Methylprednisolone (40)  ·  Alemtuzumab (35)  ·  4-Aminopyridine (34)  ·  ofatumumab (33)

Sponsors

Biogen (165)  ·  Novartis Pharmaceuticals (94)  ·  Merck KGaA, Darmstadt, Germany (49)  ·  Bayer (47)  ·  Assiut University (42)  ·  Hoffmann-La Roche (41)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (36)  ·  Sanofi (36)  ·  Hasselt University (34)  ·  Assistance Publique - Hôpitaux de Paris (33)  ·  Johns Hopkins University (33)  ·  Kessler Foundation (32)  ·  Fondazione Don Carlo Gnocchi ETS (30)  ·  Cairo University (28)  ·  University of Washington (28)

Countries

United States (1493)  ·  France (499)  ·  Italy (386)  ·  Germany (374)  ·  Turkey (Türkiye) (347)  ·  United Kingdom (333)  ·  Canada (322)  ·  Spain (301)  ·  Poland (206)  ·  Belgium (200)  ·  Czechia (182)  ·  Switzerland (168)  ·  Denmark (150)  ·  Netherlands (146)  ·  China (141)

Top investigators

Daniel S Reich, M.D. (11)  ·  Cagla Ozkul (9)  ·  Michael Levy, MD, PhD (9)  ·  Peter Feys, prof. dr. (9)

Results publications

PMID 31072380, PMID 21387374, PMID 33023488, PMID 32447743, PMID 34882037, PMID 42578463, PMID 23669008, PMID 25475413, PMID 27411694, PMID 27733070, PMID 29275977, PMID 30918100, PMID 31654272, PMID 31762387, PMID 32710396, PMID 36163349, PMID 37652990, PMID 37745914, PMID 39935588, PMID 40258203, PMID 40756531, PMID 40966534, PMID 42328798, PMID 6685237, PMID 12525714, PMID 21586746, PMID 22622860, PMID 23531349, PMID 24131282, PMID 25245812, PMID 26932146, PMID 28002679, PMID 28002688, PMID 28825348, PMID 30144037, PMID 31675266, PMID 32426039, PMID 32539719, PMID 33332761, PMID 33414927, PMID 34035833, PMID 34376508, PMID 34378446, PMID 35003076, PMID 36619856, PMID 37272540, PMID 39251561, PMID 39383458, PMID 40743487, PMID 42368888

NIH funding

2023 (26), 2014 (22), 2015 (21), 2018 (19), 2019 (18), 2016 (16), 2017 (15), 2009 (13), 2008 (12), 2025 (10), 2005 (6), 2004 (3), K23AT004433 (2), K24AT012644 (2), P30DK056336 (2)